ERBB2 and breast carcinoma: The diagnostic of amplification in the ERBB2 oncogene leading to the overexpression of the HER2 protein constitutes a paradigm for the use of biomarkers in oncology since trastuzumab, an anti-HER2 antibody, have revolutionized the outcome of ERBB2-amplified metastatic breast cancer patients [1].